56
Streamlining Cell Analysis Workflows for the Immuno-Oncology, Virology and Vaccine Development Markets
Agilent Technologies Inc has introduced an integrated solution that combines their xCELLigence RTCA HT platform with the BioTek BioSpa 8 Automated Incubator. This new development offers a higher level of workflow automation, allowing for the creation of label-free high-throughput potency assays for immuno-oncology and high-throughput viral cytopathic effects (CPE) assays for the vaccine market.
Pharmaceutical researchers in immuno-oncology and vaccine developers are seeking new ways to accelerate clinical success and respond to public health threats. While automated workflows offer the potential to increase drug candidate screening and improve the efficiency of research, many current solutions rely on manual steps that slow down throughput and restrict assay development.
The integration of xCELLigence RTCA HT and BioSpa 8 offers a non-invasive, label-free kinetic readout of cell proliferation and cytotoxicity. With the ability to analyse up to eight 384-well E-Plates, this system increases throughput and reduces sample sizes. The BioSpa 8 provides real- time temperature and CO2
/O2 control with humidity monitoring while the xCELLigence instrument is equipped with a heated cradle to protect
cells from unnecessary perturbations during the automated transfer from the incubator. Automated assays and data analysis software make this a user-friendly, walk-away system for identifying disease-fighting therapeutics, offering a level of automation unique to this technology combination.
“This is an innovative solution for immuno-oncology therapeutic and vaccine development, demonstrating Agilent’s ongoing commitment to fight cancer and infectious diseases,” said Todd Christian, Vice President and General Manager of Agilent’s Cell Analysis Division. “Integrating our non- invasive, and real-time cell analysis measurement capabilities and physiological incubation provides a simple, automated workflow for increased throughput and screening flexibility under physiological conditions.”
“The xCELLigence RTCA HT technology has been key to facilitating high-throughput, rapid, and quantitative cytopathic effect (CPE) monitoring as a tool to assess neutralising activity and potency,” said Dr Robert Carnahan, Associate Director of the Vanderbilt Vaccine Center at the Vanderbilt University Medical Center. “We were able to bypass a multitude of hands-on, multistep processes required by plaque or focus-forming assays to measure viral activity.”
More information online:
ilmt.co/PL/BKnK 59868pr@reply-direct.com Flexible Flow Chemistry System with High-Performance Modules
With a variety of high-performance modules that can be tailored to meet specific application requirements, the Uniqsis FlowLab Plus™ is a flexible flow chemistry system that offers unmatched versatility.
The FlowLab Plus™ is built with the reliable Binary Pump™ dual channel reagent delivery system and can be set up for both manual and automated flow chemistry reactions. The system’s flexibility is highlighted by its ability to support up to four separate reactor modules, which can be any combination of HotCoil™ and HotChip™ heated reactor modules, as well as Polar Bear Plus Flow™ or Polar Bear Plus GSM™ cryogenic modules. This allows for a wide operating range, spanning from -40°C to 300°C.
By incorporating the advanced FlowControl II software, the FlowLab Plus™ system can be integrated with a fraction collector, streamlining reactions through automated sample loop filling or reagent bottle usage to enable optimised reaction studies.
The FlowLab Plus™ system’s computer, pumps, and heating/cooling modules are connected via a LAN using an Ethernet hub, allowing for remote control through Wi-Fi. This convenient feature enables the control computer to be operated outside of the fume hood, providing increased flexibility and ease of use.
More information online:
ilmt.co/PL/VoLE 59943pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170 |
Page 171 |
Page 172 |
Page 173 |
Page 174 |
Page 175 |
Page 176 |
Page 177 |
Page 178 |
Page 179 |
Page 180 |
Page 181 |
Page 182 |
Page 183 |
Page 184 |
Page 185 |
Page 186 |
Page 187 |
Page 188
